Feb 23,2023

VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, and Notable Labs, Inc., a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced they have entered into a definitive merger agreement. The combined company will focus on the advancement of Notable’s proprietary Predictive Precision Medicines Platform (“PPMP”) and therapeutic pipeline focused on cancer patients with high unmet medical needs. Notable’s PPMP combines multi-dimensional biological assays and machine learning to bio-simulate a patient’s cancer treatment and predict their clinical response to the actual treatment. Concurrent with the execution of the merger agreement, a healthtech-focused investor syndicate, including existing Notable stockholders Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund, have entered into a definitive securities purchase agreement with Notable to invest $10.3 million in gross proceeds prior to the close of the proposed merger. 

COLLABORATION MERGERS & ACQUISITION

#product & service

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 05,2023

Onc.AI Raises $25 Million Series A Financing Co-Led by MassMutual and Action Potential Venture Capital

Onc.AI, a medical technology company developing a novel digital clinical management solution focused on immuno-oncology, announced today it has closed a $25 million Series A financing co-led by MassMutual and Action Potential Venture Capital (a GSK venture fund). Also participating were Life Extension Ventures and all existing investors including Blue Venture Fund, Accomplice, Digitalis Ventures, and KdT Ventures. New investor Action Potential Venture Capital invests in companies advancing the fields of bioelectronic medicines, and enabling technologies for precision medicine.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Apr 06,2022

Carevive Systems and Blue Spark Technologies Partner to Conduct Real-Time Remote Patient Monitoring Pilot

Carevive Systems announced today a partnership with Blue Spark Technologies, a leader and an innovator in wearable wireless medical device solutions. The study will integrate Carevive’s expertise in Patient Reported Outcomes (ePROs) data with Blue Spark’s TempTraq continuous wearable remote temperature monitoring solution to investigate how early fever detection can guide clinical decision-making for adult oncology patients who are at increased risk for infection. Patients in the study will report their symptoms through Carevive’s PROmpt® while wearing Blue Spark’s TempTraq®, a soft wearable patch that continuously, safely and comfortably monitors body temperature, allowing clinicians to also monitor real-time patient health data. The opportunity to learn from clinicians about these data value and patients about their reporting experience are key pilot goals.

COLLABORATION PARTNERSHIP

#connected device

#rpm

View Analyst & Ambassador Comments
Go to original news
Aug 30,2021

Quality Cancer Care Alliance and ConcertAI Partner on Novel Digital Clinical Trial Solutions, Accelerating Patient Access to Clinical Trials

ConcertAI, LLC (ConcertAI), a market leader for Real-World Evidence (RWE) and enterprise AI Software-as-a-Service (SaaS) technology solutions for precision oncology, hematology and urology, announced today that the Quality Cancer Care Alliance Network (QCCA), the first national clinically integrated network of community oncology practices, has selected ConcertAI as its exclusive partner for digital clinical trials. ConcertAI will integrate its Digital Trial Solution into QCCA's network of 18 community-based oncology practices.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 03,2020

Syneos Health and ConcertAI Announce Strategic Collaboration to Accelerate the Use of Real World Evidence and AI to Advance Oncology Research

Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization and ConcertAI, the leader in oncology real world evidence (RWE) and patient outcomes solutions for the biopharmaceutical and healthcare industries, today announced a strategic collaboration to accelerate and streamline the implementation of novel oncology clinical trial research and study designs. In a first-of-its kind CRO collaboration, ConcertAI will bring its deep experience in RWE generation, innovative RWE technologies and regulatory-grade oncology and urology real world data (RWD).

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Dec 07,2021

Labcorp forges latest AI deal, partnering with ConcertAI for cancer studies

Labcorp has teamed with ConcertAI to use the latter’s technology to optimize clinical trials of candidate cancer drug therapies. The partnership – financial terms of which were not disclosed – will see Labcorp use artificial intelligence software to aid clinical trial design, protocol optimization, site selection and study execution activities. The firms will also incorporate real-world data into the optimization process. The plan to analyze patient availability at cancer centers worldwide to ensure that the design of a trial contains a diverse set of participants to measure drug safety and effectiveness in broadly representative populations.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Sep 29,2022

Real-World Data Collab Aims to Improve Diversity in Cancer Clinical Trials

The National Cancer Institute Community Oncology Research Program (NCI NCORP)-designated Louisiana State University (LSU) Health New Orleans is collaborating with artificial intelligence (AI) and real-world data solutions company ConcertAI to improve diversity in clinical trials and ensure broader access for cancer patients. The collaboration is part of ongoing work by LSU Health New Orleans and NCI NCORP to establish and improve the clinical trials network in the Gulf South region. According to the press release, NCI awarded LSU Health New Orleans a $5.6 million grant to create the network and another $13.6 million to expand it, with an emphasis on reaching underserved and minority patients. The collaboration also aligns with ConcertAI’s ERACE (Engaging Research to Achieve Cancer Care Equality) program. "The collaboration will identify current cancer care disparities in Louisiana and how they can be addressed," said Augusto Ochoa, MD, an LSU Health New Orleans NCORP principal investigator, in the press release. 

COLLABORATION PARTNERSHIP

#institution

#rwd

View Analyst & Ambassador Comments
Go to original news
Oct 04,2021

GNS Healthcare Announces a Multi-Year Collaboration with a Leading US Cancer Center to Advance Precision Medicine in Oncology

GNS Healthcare (GNS), an artificial intelligence company creating in silico patients that simulate drug treatment at the individual patient level, today announced a multi-year collaboration with Memorial Sloan Kettering Cancer Center (MSK) to leverage longitudinal multi-modal prostate cancer patient data and world class prostate cancer expertise with GNS’ Gemini in silico Prostate Cancer patient. This collaboration will address key questions for prostate cancer patients, including identifying subtypes of aggressive disease and discovering novel drug targets and drivers of patient response to an increasing array of therapeutics. These insights will enable the design of highly sophisticated clinical trials and generate evidence of comparative effectiveness between drugs and simulate treatment sequencing. The work will build on the existing Gemini – The in silico Patient™ for Prostate Cancer developed in partnership with Tempus. 

COLLABORATION PARTNERSHIP

#r&d

#rwd

View Analyst & Ambassador Comments
Go to original news
Jan 19,2021

QIAGEN Adopts GNS Healthcare's Gemini - The in silico Patient™ Across Multiple Cancers

GNS Healthcare, the leading AI-driven precision medicine company, today announced a partnership with QIAGEN, the leading global provider of Sample to Insight solutions for molecular testing. The parties will leverage Gemini – The in silico Patient™ across multiple cancers to combine the power of causal AI technology with biomedical knowledge powered by QIAGEN's Knowledge Base to drive next-generation biological discoveries. The combined application of causal AI technology with Biomedical Knowledge will enable QIAGEN customers to discover new targets and identify prognostic markers at an accelerated rate. 

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 30,2022

Syapse and Genesis Research Form RWE Partnership in Oncology

Today, Syapse, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases, announced that they have entered into a strategic partnership with Genesis Research. As part of the partnership, Genesis Research will leverage Syapse’s leading real-world evidence platform, enabling the two companies to develop a deeper understanding of the challenges associated with complex cancers. Together, this relationship will enable Syapse to provide its clients access to Genesis’ integrated research partnerships.  

COLLABORATION PARTNERSHIP

#product & service

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY